BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling ...

BNT327/ PM8002, an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization being developed in collaboration with Biotheus: For more information, please ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.

BioNTech's first late-stage cancer trial success Phase III trial shows BNT323 slows HER2-positive breast cancer progression, companies say Companies compete with AstraZeneca-Daiichi alliance For COVID ...

Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese phase 2 ...